MedTrace Logo

Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study

NCT04964310 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 339

Last updated 2025-02-26

No results posted yet for this study

Summary

Acetaminophen (APAP) is the most commonly used NSAIDS in clinic, and it is also a common cause of drug-induced liver injury (DILI). In 2012, the proportion of DILI caused by APAP in the United States was 51%, while in Asia, it was only 7.10%. Previously, a small cohort study in the United States screened for some of the susceptibility genes for DILI due to APAP by the Genome wide association study (GWAS) method. However, the genetic susceptibility loci based on the US cohort were not applicable to the Chinese population. Therefore, we make a study design include Chinese population who ingested APAP and divided them into case group and control group according to the occurrence of DILI. We hope to be able to find the root of differences at the genetic level and explore new pathogenic mechanisms.

Conditions

  • Acetaminophen
  • Drug-Induced Liver Injury
  • Pharmacogenetics
  • China

Interventions

GENETIC

genetic polymorphism

Observe the genetic polymorphism frequency difference between case and control groups

Sponsors & Collaborators

  • University of Colorado, Denver

    collaborator OTHER

  • Beijing Genomics Institute

    collaborator OTHER

  • Nanjing Medical University

    collaborator OTHER

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • Jingsong Zhang, professor · The First Affiliated Hospital with Nanjing Medical University

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-31
Primary Completion
2025-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04964310 on ClinicalTrials.gov